We next examined the association of these genes with on-treatment Ki67 levels in three clinical studies of ER+ breast cancers treated with a neoadjuvant aromatase inhibitor (Supplementary Table 1; cohort of Guerrero-Zotano17; cohort of Giltnane14; cohort of Miller22). The gene discussed is CYP19A1; the disease is breast cancer.